在干血斑点中,用高性能液态染色学-光二极管阵列检测氨酸的药理动力学概况
Yahdiana Harahap1,2, Limeylia Ng1, Sunarsih Sunarsih3
1Bioavailability/Bioequivalence Laboratory, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
Frontiers in pharmacology
|July 11, 2024
概括
干血斑点 (DBS) 分析为量化抗药物芬伊托因提供了一种有效的替代方案. 这种方法提供了与传统血分析相比较的药理动力学概况,具有较小样本体积和更容易运输的额外好处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分析化学 分析化学
- 临床药房 临床药房
背景情况:
- 氨酸是一种关键的第一线抗药物,具有狭窄的治疗指数.
- 氨酸的非线性药理动力学需要准确可靠的量化方法.
- 传统的等离子体分析存在几个后勤缺点.
研究的目的:
- 在干血斑点 (DBS) 中部分验证一种分析方法来定量芬伊托因.
- 在健康受试者中使用DBS来确定芬伊托因的药理动力学概况.
- 为了比较DBS与血矩阵中的芬伊托因药理动力学.
主要方法:
- 用光二极管阵列 (PDA) 探测器进行逆相高性能液体染色学 (RP-HPLC) 分析了氨酸和碳氨酸 (内部标准).
- 部分验证包括对线性,运行准确性和精度的评估.
- 药物动力学参数是从六名健康志愿者的DBS样本中计算出来的.
主要成果:
- 分析方法在定义的标准中证明了可接受的线性,准确性和精度.
- 在DBS中的平均AUC0-t和AUC0-∞分别为83.81±37.32μg.h/mL和83.65±38.89μg.h/mL.
- 来自DBS的度-时间曲线与历史血数据可比,表明具有相似的药理动力学特征.
结论:
- 在DBS中开发的氨酸的分析方法适合于药理动力学研究.
- DBS提供了一个可行的,舒适和高效的替代品,用于血的氨酸量化.
- DBS分析可以与血分析交替使用,用于监测芬伊托因治疗.
更多相关视频
相关概念视频
Drug Concentrations: Measurements
355
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
355
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
156
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
156
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
119
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
119
Drug Concentration Versus Time Correlation
715
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
715
High-Performance Liquid Chromatography: Types of Detectors
529
The role of the detectors in High-Performance Liquid Chromatography (HPLC) is to analyze the solutes as they exit from the chromatographic column. The detector recognizes the solute's property and generates corresponding electrical signals, which are converted into a readable graph of the detector's response versus elution time called a chromatogram at the computer. There are several types of HPLC detectors, each with its own advantages and limitations, depending on the analyte...
529


